Viridian Therapeutics Inc

NASDAQ:VRDN   11:46:13 AM EDT
17.70
+0.48 (+2.79%)
Products, Regulatory

Viridian Therapeutics Announces First Subject Dosed In Phase 1/2 Clinical Trial Of Vrdn-001 For Thyroid Eye Disease

Published: 12/20/2021 12:24 GMT
Viridian Therapeutics Inc (VRDN) - Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of Vrdn-001 for Thyroid Eye Disease (ted).
Viridian Therapeutics Inc- Vrdn-001 Targets and Blocks Igf-1r, Only Mechanism of Action Proven to Deliver Efficacy in Ted.
Viridian Therapeutics Inc- Trial is on Track to Deliver Top Line Proof of Concept Clinical Data in 2q 2022.